Plain-English translation of NCT06788990 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , a new medication that targets two different cancer growth pathways, works better than a placebo when combined with pembrolizumab (an immunotherapy drug) for treating advanced head and neck cancer. The study has two phases: first, researchers will determine the best dose of this medication, then they'll test whether that dose truly helps patients live longer and have better outcomes compared to those receiving placebo plus the immunotherapy alone.
Head and neck cancer that has spread or come back is difficult to treat, and current options don't work well enough for many patients. This new treatment is designed to attack cancer cells in two different ways at once, and early results suggest it might be more effective when combined with existing immunotherapy.
You likely qualify if…
You likely don't qualify if…
You will receive either the new medication (at one of two different doses) or a placebo, given as an injection once per week, plus the immunotherapy drug pembrolizumab given every three weeks. The study starts with a phase to find the safest and most effective dose, then moves to a larger phase to confirm whether the treatment works. You'll have regular clinic visits for infusions, blood tests, and imaging scans to monitor how well the treatment is working and check for side effects.
AI-generated summary from trial data · Oct 7, 2026 · Not medical advice
United States